News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
105last 24h
3126last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
MT Newswires6d agobullish
RBC Raises Price Target on AbbVie to $330 From $280, Keeps Outperform RatingSimply Wall St.8d agobullish
Is Earnings Beat Altering The Investment Case For AbbVie Stock (ABBV)?MarketWatch64d agobullish
Plastic surgery is booming with boomers. Here’s how to cash in on the antiaging craze.Investing.com87d agobullish
Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation24/7 Wall St.89d agobullish
Eli Lilly Beat Big and Raised Guidance. Wall Street Sees More Room to RunThe Wall Street Journal100d agobullish
AbbVie Lowers Outlook to Account for Acquisition as Profit JumpsBarrons.com100d agobullish
AbbVie Bought Apogee to Strengthen Its Portfolio. Now It’s Cutting Earnings Guidance.Investor's Business Daily103d agobullish
Botox Maker Tops Buy Point, But Here Comes The Earnings ReportInvestor's Business Daily125d agobullish
Johnson & Johnson, IBD Stock Of The Day, In Buy Zone Heading Into EarningsMotley Fool131d agobullish
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?Motley Fool139d agobullish
Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout OfferPharmaceutical Technology139d agobullish
AbbVie deepens immunology legacy in $10.9bn Apogee buyoutThe Wall Street Journal139d agobullish
AbbVie to Buy Apogee Therapeutics for $10.9 Billion in CashInsider Monkey139d agobullish
AbbVie’s (ABBV) Allergan Aesthetics Wins FDA Approval for Skinvive by Juvederm24/7 Wall St.158d agobullish
AbbVie Delivers 400% Returns Beating The S&P 500 by 139%Simply Wall St.179d agobullish
A Look At AbbVie (ABBV) Valuation After New Immunology Data And Upgraded 2026 Earnings Outlook